Terms: = Bone cancer AND JAK2, ENSG00000096968, O60674, JTK10, 3717
692 results:
1. Secondary Polycythemia and Non-Islet Cell Tumor-induced Hypoglycemia in Advanced Hepatocellular Carcinoma: A Case Report.
Paramitha MS; Esa DF; Hustrini NM; Mulansari NA; Hasan I; Harahap AS
Acta Med Indones; 2024 Jan; 56(1):93-101. PubMed ID: 38561874
[TBL] [Abstract] [Full Text] [Related]
2. Altered erythropoiesis via jak2 and ASXL1 mutations in myeloproliferative neoplasms.
Collins TB; Laranjeira ABA; Kong T; Fulbright MC; Fisher DAC; Sturgeon CM; Batista LFZ; Oh ST
Exp Hematol; 2024 Apr; 132():104178. PubMed ID: 38340948
[TBL] [Abstract] [Full Text] [Related]
3. Exploring the Molecular Aspects of Myeloproliferative Neoplasms Associated with Unusual Site Vein Thrombosis: Review of the Literature and Latest Insights.
Morsia E; Torre E; Martini F; Morè S; Poloni A; Olivieri A; Rupoli S
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338802
[TBL] [Abstract] [Full Text] [Related]
4. Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma.
Del Dosso A; Tadevosyan E; Berenson JR
Oncotarget; 2024 Feb; 15():65-75. PubMed ID: 38319731
[TBL] [Abstract] [Full Text] [Related]
5. Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A; Vannucchi AM; Barbui T
Am J Hematol; 2024 Apr; 99(4):697-718. PubMed ID: 38269572
[TBL] [Abstract] [Full Text] [Related]
6. jak2V617F Reversible Activation Shows Its Essential Requirement in Myeloproliferative Neoplasms.
Dunbar AJ; Bowman RL; Park YC; O'Connor K; Izzo F; Myers RM; Karzai A; Zaroogian Z; Kim WJ; Fernández-Maestre I; Waarts MR; Nazir A; Xiao W; Codilupi T; Brodsky M; Farina M; Cai L; Cai SF; Wang B; An W; Yang JL; Mowla S; Eisman SE; Hanasoge Somasundara AV; Glass JL; Mishra T; Houston R; Guzzardi E; Martinez Benitez AR; Viny AD; Koche RP; Meyer SC; Landau DA; Levine RL
Cancer Discov; 2024 May; 14(5):737-751. PubMed ID: 38230747
[TBL] [Abstract] [Full Text] [Related]
7. Combination of minimal residual disease on day 15 and copy number alterations results in BCR-ABL1-negative pediatric B-ALL: A powerful tool for prediction of induction failure.
Baghdadi H; Soleimani M; Zavvar M; Bahoush G; Poopak B
Cancer Genet; 2024 Apr; 282-283():27-34. PubMed ID: 38183785
[TBL] [Abstract] [Full Text] [Related]
8. Myeloid and lymphoid neoplasm with novel complex translocation: unusual case report with T-lymphoblastic lymphoma, myeloid hyperplasia, eosinophilia, basophilia, and t(1;8;10)( (p31;q24;q11.2).
Aljabry MS
J Hematop; 2023 Mar; 16(1):27-31. PubMed ID: 38175368
[TBL] [Abstract] [Full Text] [Related]
9. Incidence of blast phase in myelofibrosis patients according to anemia severity at ruxolitinib start and during therapy.
Palandri F; Palumbo GA; Benevolo G; Iurlo A; Elli EM; Abruzzese E; Polverelli N; Tiribelli M; Auteri G; Tieghi A; Caocci G; Binotto G; Cavazzini F; Branzanti F; Beggiato E; Miglino M; Bosi C; Crugnola M; Bocchia M; Martino B; Pugliese N; Scaffidi L; Venturi M; Duminuco A; Isidori A; Cattaneo D; Krampera M; Pane F; Cilloni D; Semenzato G; Lemoli RM; Cuneo A; Trawinska MM; Vianelli N; Cavo M; Bonifacio M; Breccia M
Cancer; 2024 Apr; 130(8):1270-1280. PubMed ID: 38153814
[TBL] [Abstract] [Full Text] [Related]
10. A newly identified 45-kDa jak2 variant with an altered kinase domain structure represents a novel mode of jak2 kinase inhibitor resistance.
Gorantla SP; Mueller TA; Albers-Leischner C; Rudelius M; von Bubnoff N; Duyster J
Mol Oncol; 2024 Feb; 18(2):415-430. PubMed ID: 38104968
[TBL] [Abstract] [Full Text] [Related]
11. The highs and lows of cyclic thrombocytopenia.
Zhang H; Villar-Prados A; Bussel JB; Zehnder JL
Br J Haematol; 2024 Jan; 204(1):56-67. PubMed ID: 38083878
[TBL] [Abstract] [Full Text] [Related]
12. jak2 R683S Mutation Resulting in Dual Diagnoses of Chronic Eosinophilic Leukemia and Myelodysplastic/Myeloproliferative Overlap Syndrome.
Krah NM; Miotke L; Li P; Patel JL; Bowen AR; Pomicter AD; Patel AB
J Natl Compr Canc Netw; 2023 Dec; 21(12):1218-1223. PubMed ID: 38081125
[TBL] [Abstract] [Full Text] [Related]
13. High cell-free DNA is associated with disease progression, inflammasome activation and elevated levels of inflammasome-related cytokine IL-18 in patients with myelofibrosis.
De Luca G; Lev PR; Camacho MF; Goette NP; Sackmann F; Castro Ríos MA; Moiraghi B; Cortes Guerrieri V; Bendek G; Carricondo E; Enrico A; Vallejo V; Varela A; Khoury M; Gutierrez M; Larripa IB; Marta RF; Glembotsky AC; Heller PG
Front Immunol; 2023; 14():1161832. PubMed ID: 38035089
[TBL] [Abstract] [Full Text] [Related]
14. [Expression level of Wilms' tumor 1 gene and its correlation with clinical features in patients with myeloproliferative neoplasms].
Liu C; Wu SY; Zhang AB; Luo P; Zhou Y; Liu Y; Zuo XL
Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3658-3664. PubMed ID: 38018065
[No Abstract] [Full Text] [Related]
15. CD45 inhibition in myeloid leukaemia cells sensitizes cellular responsiveness to chemotherapy.
Al Barashdi MAS; Ali A; McMullin MF; Mills K
Ann Hematol; 2024 Jan; 103(1):73-88. PubMed ID: 37917373
[TBL] [Abstract] [Full Text] [Related]
16. The utility of testing erythropoietin level in polycythemia diagnosis.
Ismail A; Abdalla E; Aqel A; Fadul A; Ahmed A; Alsayed A; Musa M; Yassin MA
Hematology; 2023 Dec; 28(1):2269510. PubMed ID: 37843428
[TBL] [Abstract] [Full Text] [Related]
17. Asymptomatic Essential Thrombocytosis Presenting with Extrahepatic Portal Vein Thrombosis: A Case Report.
Yakami Y; Yagyu T; Bando T; Hanada M
Am J Case Rep; 2023 Sep; 24():e938547. PubMed ID: 37766423
[TBL] [Abstract] [Full Text] [Related]
18. U2AF1 pathogenic variants in myeloid neoplasms and precursor states: distribution of co-mutations and prognostic heterogeneity.
Badar T; Vanegas YAM; Nanaa A; Foran JM; Al-Kali A; Mangaonkar A; Murthy H; Alkhateeb HB; Viswanatha D; He R; Shah M; Yi CA; Litzow MR; Gangat N; Tefferi A; Patnaik MM
Blood Cancer J; 2023 Sep; 13(1):149. PubMed ID: 37735430
[TBL] [Abstract] [Full Text] [Related]
19. Allogeneic hematopoietic cell transplantation in patients with CALR-mutated myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT.
Hernández-Boluda JC; Eikema DJ; Koster L; Kröger N; Robin M; de Witte M; Finke J; Finazzi MC; Broers A; Raida L; Schaap N; Chiusolo P; Verbeek M; Hazenberg CLE; Halaburda K; Kulagin A; Labussière-Wallet H; Gedde-Dahl T; Rabitsch W; Raj K; Drozd-Sokolowska J; Battipaglia G; Polverelli N; Czerw T; Yakoub-Agha I; McLornan DP
Bone Marrow Transplant; 2023 Dec; 58(12):1357-1367. PubMed ID: 37679647
[TBL] [Abstract] [Full Text] [Related]
20. Regulating Tumorigenicity and cancer Metastasis through TRKA Signaling.
Fan Y; Zhang B; Du X; Wang B; Yan Q; Guo L; Yao W
Curr Cancer Drug Targets; 2024; 24(3):271-287. PubMed ID: 37670705
[TBL] [Abstract] [Full Text] [Related]
[Next]
